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Abstract
Background: Opioids are a mainstay for the treatment of chronic pain. Unfortunately, therapy-limiting maladaptations
such as loss of treatment effect (tolerance), and paradoxical opioid-induced hyperalgesia (OIH) can occur. The objective
of this study was to identify genes responsible for opioid tolerance and OIH.
Results: These studies used a well-established model of ascending morphine administration to induce tolerance, OIH
and other opioid maladaptations in 23 strains of inbred mice. Genome-wide computational genetic mapping was then
applied to the data in combination with a false discovery rate filter. Transgenic mice, gene expression experiments and
immunoprecipitation assays were used to confirm the functional roles of the most strongly linked gene. The behavioral
data processed using computational genetic mapping and false discovery rate filtering provided several strongly linked
biologically plausible gene associations. The strongest of these was the highly polymorphic Mpdz gene coding for the
post-synaptic scaffolding protein Mpdz/MUPP1. Heterozygous Mpdz +/− mice displayed reduced opioid tolerance and
OIH. Mpdz gene expression and Mpdz/MUPP1 protein levels were lower in the spinal cords of low-adapting 129S1/
Svlm mice than in high-adapting C57BL/6 mice. Morphine did not alter Mpdz expression levels. In addition, association
of Mpdz/MUPP1 with its known binding partner CaMKII did not differ between these high- and low-adapting strains.
Conclusions: The degrees of maladaptive changes in response to repeated administration of morphine vary greatly
across inbred strains of mice. Variants of the multiple PDZ domain gene Mpdz may contribute to the observed
inter-strain variability in tolerance and OIH by virtue of changes in the level of their expression.
Keywords: Opioid analgesics, Drug tolerance, Gene mapping, Synaptic plasticity
Background
The US Centers for Disease Control (CDC) has declared
opioid prescribing to be at epidemic levels [1]; use of
these drugs primarily for the treatment of chronic pain
has increased exponentially over the past 15 years in the
US and many other Western nations [2]. Unfortunately,
opioid therapy is often accompanied by opioid dose
escalation, loss of treatment effect, progression of pain
complaints and disability. For example, more than 1/3rd
of chronic pain patients double their oral opioid doses in
the first few years of treatment [3], and those treated
with intrathecal opioids experience 12–17 % increases in
opioid doses each year on average [4]. Moreover, clinical
studies have shown greater pain sensitivity in chronic
pain patients treated with opioids with changes propor-
tional to the duration of therapy and the doses used [5].
Equally concerning, opioid dose escalation either in the
setting of acute injury or when used to provide analgesia
for chronic pain patients is associated with increased
risks of side effects, abuse, overdose and death [6]. These
problems involving loss of treatment effect and conse-
quent dose escalation are believed to be caused in large
part by maladaptations such as tolerance and the related
phenomenon of opioid-induced hyperalgesia (OIH) [7].
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We have no clinically available strategies effective in
preventing or reversing these changes.
Genetic approaches to understanding opioid maladap-
tations offer the advantage of taking a hypothesis-free
approach to the identification of underlying mechanisms.
Laboratory studies using inbred mice demonstrate that
analgesic tolerance, physical dependence and opioid-
induced hyperalgesia all display a very large degree of
heritability (>60 %) [8–11]. Likewise, numerous studies
conducted in mice have identified quantitative trait loci
(QTLs) and individual genes linked to specific maladapta-
tions such as tolerance [12], dependence [13, 14] and OIH
[9, 15]. In the case of the β2-adrenergic receptor linked to
OIH and the 5-HT3 receptor linked to physical depend-
ence, the murine genetic findings were confirmed in small
translational trials in humans [13, 16].
Haplotype-based computational genetic mapping
(HBCGM) has recently advanced to the point that whole-
genome sequence data can be used to identify genetic
factors affecting drug responses [17]. Using this approach,
we recently found that the Dcc gene affects OIH and
tolerance [18]. However, highly polymorphic genes have
a relatively high probability for matching unrelated
phenotypes by HBCGM due to the large number of
haplotype blocks that can be formed within the gene.
This effect can be particularly problematic when multiple
different phenotypes are evaluated. Hence, a more accur-
ate ranking of genes can be obtained if we correct for the
false discovery rate (FDR) of each gene [19]. In this set
of studies, we use a newly derived method for FDR
correction in combination with data from multiple opi-
oid maladaptation phenotypes to reproduce the earlier
Dcc association and to identify a novel gene regulating
clinically important maladaptations to opioids.
Results
Haplotype-based computational genetic mapping of
opioid maladaptations
Six opiate responses were analyzed in 23 inbred strains,
which include: mechanical hindpaw OIH, thermal hindpaw
OIH, thermal tail flick OIH, morphine analgesic tolerance,
physical dependence and morphine-induced changes in
body mass (Figs. 1 and 2). For this analysis, HBCGM was
first applied to each phenotype individually. Each analysis
produced a list of genes (not corrected for FDR) with
patterns of allelic variation that were associated with
each phenotype. We then analyzed the results obtained
for 6 opioid adaptation phenotypes in an integrated
fashion (Table 1). The output of the integrative analysis
identifies the genes exhibiting the strongest association
to all six phenotypes.
In order to correct for false discovery, we applied FDR
correction methodology to the individual phenotype map-
ping results prior to integrating across the phenotypes.
The grouped analysis results after FDR and integration are
also given in Table 2. Of note, without FDR filtering,
Mpdz was ranked 26th, whereas after FDR filtering Mpdz
was ranked 1st. The three phenotypes contributing most
strongly to the ranking of Mpdz in the FDR corrected
mapping results were tolerance, mechanical hindpaw OIH
and weight loss. The Dcc gene associated with a more lim-
ited set of opioid maladaptive traits for these 23 strains
and also appears on the final list, though at a lower
position than previously found [18]. The Mpdz gene has
been demonstrated to be involved in synaptic functions
including long-term potentiation to which spinally-
mediated opioid maladaptations such as tolerance and
hyperalgesia have been compared [20, 21]. The Sgcz gene
listed in second position in Table 1 dropped out of the top
10 most strongly after application of the FDR correction
to 60th position, but was still strongly correlated with the
physical dependence/jumping phenotype.
The Mpdz gene on chromosome 4 codes for the
MUPP1 protein. It is greater than 1.6 Mb in length and
contains 676 SNPs, which are present in regulatory and
coding regions. Ten SNPs alter the predicted amino acid
sequence of MUPP1 (Table 3). Of note the alleles at 8 of
these SNPs are shared by the 6 strains with highest and
lowest levels of opioid adaptation. One allelic substitu-
tion (H1767N) occurs at an amino acid position that is
conserved across humans and 6 mammalian species. It
is located within a PDZ domain in MUPP1 has been
shown to be critical for interaction with CaMKII [22],
which is a kinase whose spinal activity is critical for the
development of tolerance and OIH [23–25].
Mpdz expression in spinal cord tissue
A change in either Mpdz expression levels or in the
function of the mature MUPP1 protein could contribute
to the observed maladaptive differences among the inbred
strains. To determine if differences in Mpdz expression
differed between strains with divergent opioid phenotypes,
we examined spinal cord tissue, which a principal center
responsible for opioid tolerance and OIH [26]. We se-
lected the C57BL/6 and 129S1/SvIm strains as representa-
tive of strongly adaptive and adaptation-resistant strains,
respectively. The spinal cord tissue of the C57BL/6 mice
had higher levels of Mpdz mRNA (Fig. 3a) and protein
(Fig. 3b) than the 129S1/SvIm animals. Moreover, mor-
phine treatment did not alter mRNA levels in either strain.
Mpdz knockdown and morphine maladaptations
In order to test the functional role of Mpdz in opioid
maladaptations in mice, we tested littermate wild-type
and Mpdz +/− heterozygous mice in the C57BL/6 back-
ground. These heterozygous mice have CNS Mpdz/
MUPP1 levels that are 47 % of those found in wild type
mice [27]. While the heterozygous mice have normal
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baseline mechanical nociceptive thresholds, they do not
develop OIH to the degree displayed by the wild-type
mice (Fig. 4). In addition, analgesic tolerance to morphine
is reduced in these heterozygous animals though drug
naïve morphine sensitivity was not found to differ between
the strains. On the other hand, Mpdz heterozygous mice
did not display altered physical dependence, nor was the
degree of weight loss different after morphine treatment.
Mpdz/MUPP1 interaction with CaMKII
Earlier work described the interaction of CaMKII with
MUPP1 as a key event governing the activation of
NMDA receptors in hippocampal neurons [28]. This
has relevance to morphine treatment as both NMDA
receptor activation and CaMKII activity in spinal tis-
sue are critical for opioid tolerance and OIH [24, 29].
Co-immunoprecipitation experiments were performed
to identify synaptosomal proteins that co-precipitated
with MUPP1. After precipitation of MUPP1 protein
using an anti-MUPP1 antibody, the amount of associ-
ated CaMKII was quantified by immunoblot analysis.
Although CaMKII co-precipitated with MUPP1, there
was not a difference in the amount of associated CaMKII
after morphine treatment in the high adaptive strains
Fig. 1 Opioid-induced changes in nociceptive thresholds for 23 strains of mice. These data were reproduced from our earlier report [18]. In panel (a)
the reduction in mechanical nociceptive thresholds are displayed as a fraction of the baseline thresholds. The strains are displayed from the most to
least robustly changed. In panel (b) thermal withdrawal thresholds measured using a Hargreaves’ apparatus are displayed as a fraction of baseline
threshold. In panel (c) changes in thermal withdrawal threshold of the tail (tail flick) response are provided. For each trait the mean value is displayed
+/− S.E.M., n = 8 mice per strain
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(Fig. 5a). Since the 129S1/Svlm strain possesses an
amino acid substitution within the CaMKII binding re-
gion of MUPP1 (H1767N), we hypothesized we would
observe lower CaMKII co-immunoprecipitation with
MUPP1 in mouse spinal cord synaptosomes made from
129S1/Svlm animals. Although 129S1/Svlm mice may
possess less MUPP1 in their spinal cord tissue, the
relative amount of CaMKII co-precipitating with the
MUPP1 protein was the same in spinal cord tissue ob-
tained from C57BL/6 and 129S1/Svlm mice (Fig. 5b).
Additional experiments quantifying activated (Thr-286)
phospho-CaMKII in the MUPP1 immunoprecipitates
also failed to identify strain or morphine effects (data
not shown).
Fig. 2 Morphine tolerance, dependence and weight change for 23 strains of mice. Some data were reproduced from our earlier report [18]. In
panel (a) the fold change in the ED50 values for morphine dose–response curves are provided. In panel (b) the number of jumps exhibited by
the mice in the 15 min period following the administration of naloxone are displayed. In panel (c) the change in weight as a fraction of baseline
for each of the 23 strains used in these experiments are provided. For each trait the mean value is displayed +/− S.E.M., n = 8 mice per strain
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Discussion
Despite their undisputed efficacy and wide-spread use
for the relief of acute pain, the chronic use of opioids is
limited by maladaptations, most importantly tolerance
and opioid-induced hyperalgesia (OIH). Dose escalation
caused by these maladaptations has been associated with
poor functional outcomes, greater rates of overdose and
death [6]. Little progress has been made in designing
strategies to limit or reverse these problems. Whole-
genome genetic mapping studies offer the possibility of
identifying new mechanisms underlying key maladapta-
tions that might be targeted using novel treatment strat-
egies. Unfortunately, this form of mapping is prone to
high rates of false discovery due to the number of com-
parisons made in performing whole-genome studies.
Our approach of using a false discovery rate (FDR) cor-
rection in combination with an integration of mapping
results across opioid adaptive phenotypes helps to make
the mapping results more reliable. In these studies the
Mpdz gene was associated with maladaptive opioid
phenotypes, and was confirmed as a gene relevant to
these phenotypes using Mpdz +/− heterozygous mice.
This result suggests that we look more closely at the
Mpdz/MUPP1 protein and the pathways in which it
participates in understanding and treating opioid toler-
ance and OIH.
A novel aspect of the HBCGM analysis in this study
was correcting for the tendency of highly polymorphic
genes to show up as being associated with many pheno-
types. To address this problem we randomized the
mapping from strain names to phenotype measurements
many times, and excluded genes that matched too many
of the randomized phenotypes. We then ranked genes
by a composite score based on their associations with all
six related phenotypes. The combination of these
methods resulted in the Mpdz gene being ranked first,
attracting our attention. Using previously described
whole genome mapping approaches the Mpdz gene was
ranked much lower in the list of associated genes
(Table 1). On the other hand, a gene previously shown
to be highly associated with these phenotypes and
confirmed to play a functional role using transgenic
animals and biochemical analyses, Dcc, remained rela-
tively highly correlated.
It should be realized that additional genetic contributors
might be discovered if other measures of OIH were used.
We selected a thermal and a mechanical measure to pro-
vide some phenotypic diversity and to make the measure-
ment of OIH practical in large numbers of mouse strains.
However, models of inflammatory and incisional pain with
different mechanisms and transmission pathways also
show heightened nociceptive responses after chronic opi-
oid administration [30, 31]. Likewise, a non-thermal
stimulus could be used to test analgesic tolerance al-
though most alternatives would be more laborious espe-
cially for use in large numbers of animals. Nevertheless,
these might be used in separate mapping studies, or at
least the genes discovered using simple models could be
tested for relevance in other settings.
Table 2 Rank of genes associated the opioid adaptive phenotypes
after FDR correction. While the Dcc gene remained highly

















Table 1 Rank of genes associated with 6 opioid adaptive
phenotypes before FDR correction. While the Dcc gene was
most strongly associated with the adaptive phenotypes, Mpdz
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The MUPP1 protein was originally isolated as a part-
ner of the 5-HT2C receptor [32]. Analysis of the protein
revealed 13 PDZ domains thus leading to an alternative
name (multi-PDZ-domain protein, Mpdz). A short time
later the corresponding murine Mpdz gene on chromo-
some 4 was identified and sequenced [33]; the corre-
sponding protein has a predicted molecular weight of
218 kDa. PDZ domains such as those on MUPP1 repre-
sent key structures for protein-protein interaction [34],
and are frequently found near sites of cell-cell inter-
action such as synapses and tight junctions. Indeed
several protein partners for MUPP1 have been identified
in tight junctions including claudin proteins [35, 36], a
somatostatin receptor (SSTR3) [37], and a potassium ion
channel (Kir4.2) [38]. Likewise MUPP1 has been local-
ized to synapses in the CNS where the protein is widely
expressed [39]. It is the synaptic expression of this gene
that may be responsible for the apparent role of Mpdz/
MUPP1 in tolerance and OIH. In this regard it is notable
that another post-synaptic PDZ domain containing
scaffolding protein, PSD95, is also thought to be involved
in opioid maladaptations [40, 41].
MUPP1 is a key protein both facilitating the organization
of neural synapses and in facilitating synaptic plasticity.
Identified binding partners in mammalian synapses for
MUPP1 in addition to the originally described 5-HT2C re-
ceptor interaction include CADM1 [42], connexin 36 [43],
RhoA guanine nucleotide exchange factor (GEF) [44],
CaMKII, the GABAB receptor [45], SynGAP [28] and the
NMDA receptor subunit NR2B [28]. It has been hypothe-
sized that PDZ-containing proteins such as PSD-95 and
MUPP1 may bring intracellular signaling molecules into
proximity with cell surface receptors to enhance signaling
efficiency. Specifically, MUPP1 brings the NMDA receptor,
CaMKII and SynGAP into close post-synaptic proximity
[28]. The activation of NMDA receptors then leads to the
activation of a MUPP1-facilitated cascade ultimately caus-
ing the insertion of AMPA receptor/channels into the
membrane, and persistent facilitation of glutamate signal-
ing. This pathway may contribute to phenomena such as
Table 3 Codon changing SNPs in the murine Mpdz gene. Ten variants were identified and are listed in the leftmost column. The
table also provides the identity of each of the codon changing SNPs for the six least robustly opioid adapting (left) and six most
robustly adapting strains (right). Possession of the common variant is indicated by a blue bar
Fig. 3 Mpdz expression and MUPP1 levels in mouse spinal cord
tissue. In these experiments the effects of both genotype and
morphine treatment were evaluated. Panel (a) provides the results
of qPCR experiments in which the index C57BL/6 and low-adapting
129S1/SvIm strains were used. Baseline Mpdz levels were lower in
the 129S1/SvIm strain, but the levels of Mpdz mRNA were unchanged
by morphine treatment in both of the strains tested. In panel (b) the
results of Western analysis are provided demonstrating that 129S1/
SvIm mice have lower spinal levels of Mpdz/MUPP1 protein. For each
trait the mean value is displayed +/− S.E.M., n = 6 mice per group.
*p < 0.05, ***p < 0.001
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long-term potentiation (LTP) or alternative forms of en-
hanced AMPA receptor mediated activity [46].
Both opioid analgesic tolerance and OIH are reliant
upon molecules with which MUPP1 interacts. For ex-
ample, the pharmacological blockade of NMDA receptors
and genetic deletion of NMDA receptor subunits both
limit tolerance and OIH after chronic morphine adminis-
tration in mice and rats [29, 47]. The NR2B subunits of
NMDA receptors are specifically involved in morphine
tolerance [48, 49]. Likewise, morphine enhances the spinal
expression and phosphorylation of CaMKII, and the spinal
administration of CaMKII inhibitors reduces the tolerance
Fig. 4 Opioid adaptations in C57BL/6 wild-type and Mpdz+/− mice. In panel (a) the results of experiments measuring opioid-induced hyperalgesia
using changes in mechanical withdrawal thresholds are displayed. In panel (b) the anangesic effect of cumulitive doses of morphine are shown
for wild-type and Mpdz+/− mice both before and after 4 days of escalating dose morphine treatment. In panel (c) naloxone-induced jumping
behavior for wild-type and Mpdz+/− mice is displayed. Finally, in panel (d) data for morphine-induced weight loss are provided. For each
trait the mean value is displayed +/− S.E.M., n = 8 mice per strain. ##, **p < 0.01, ###, ****p < 0.001
Fig. 5 Co-immunoprecipitation of MUPP1 with CaMKII in mouse spinal cord tissue. Spinal cord synaptosomes were first incubated with anti-MUPP1
(or IgG as a negative control). After column purification, the immune complexes were eluted and separated on acrylamide gels. Blots were
probed with anti-CaMKII to quantify MUPP1-CaMKII association. Panel (a) provides the results of co-immunoprecipitation experiments demonstrating
that MUPP1-CaMKII association is unchanged by morphine treatment in C57BL/6 mice. In panel (b) the results suggest MUPP1 protein from 129S1/
Svlm and C57BL/6 mice bind CaMKII similarly. For each measurement the mean value is displayed +/− S.E.M., n = 6 mice per group
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and OIH displayed in response to chronic morphine ad-
ministration [24, 25]. Moreover, the enhanced activity of
AMPA channels has been demonstrated to play a role
in morphine tolerance as well [50, 51]. A central role
for MUPP1 in integrating synaptic NMDA-CaMKII-
AMPA signaling has been demonstrated in hippocam-
pal tissue [28]. While our results did not demonstrate any
obvious effects of MUPP1 sequence variation between
two mouse strains with very different propensities to de-
velop opioid maladaptations (129Svlm and C57BL/6), the
approximately 50 % lower synaptic levels of MUPP1 in the
129Svlm mice provide a plausible basis for reduced opioid
maladaptation by this strain. Consistent with this hypoth-
esis, Mpdz+/− mice, that also have about 50 % less CNS
Mpdz MUPP1 protein [52], demonstrated less tolerance
and OIH in our experiments. Thus the mapping result
associating Mpdz with tolerance and OIH but not basal
analgesic potency seems to fit well with our current un-
derstanding of maladaptations related to opioid use. Be-
yond opioids, Mpdz has been associated with alcohol and
sedative dependence both in mouse and human genetic
studies demonstrating that this gene may regulate chronic
drug administration effects in multiple classes [53–55].
Much work has been done on the mechanisms sup-
porting tolerance, OIH and other maladaptations to the
use chronic use of opioids. These phenomena both limit
the clinical utility of the drugs, and place patients at ele-
vated risk of addiction and overdose. Regretably we have
no appraoches to delaying the onset or reducing the
severity of the maladaptations. Through whole-genome
mapping utilizing a new FDR-corrected approach we
have demonstrated, however, that novel mechanisms
suporting opioid maladaptations can be discovered. We
hope that by targeting the protein gene products or
perhaps identifying other critical molecules in the in-
volved signaling pathways, we might develop useful
therapeutic approaches. In the case of Mpdz/MUPP1,
the central role of synaptic plasticity is highlighted.
Methods of disrupting protein-PDZ interactions, excita-
tory amino acid signaling or possibly CaMKII activation
may be plausible approaches.
Conclusions
Our results suggest that the Mpdz gene helps to control
key clinically relevant maladaptations to morphine ad-
ministration in mice. The basis for the genetic effects
may be related to differences in gene expression in
spinal cord tissue as levels of Mpdz expression varied
between mouse strains, but the ability to interact with at
least one important binding partner, CaMKII, did not.
On the other hand, we have explored only the top-most
gene candidate that resulted from our analyses. Other
highly ranked genes such as Atrnl1 or Chn2 might be
pursued as well given there robust association with the
maladaptive phenotypes under study. Beyond opioid re-
sponses, however, these results suggest whole-genome
HBCGM with appropriate FDR correction and the inte-
gration of results from the mapping of related pheno-
types might provide insight into numerous phenotypes
measurable in common strains of inbred mice.
Methods
Animal care and use
All experimental protocols were approved by Veterans
Affairs Palo Alto Healthcare System Institutional Animal
Care and Use Committee prior to beginning the experi-
mentation. Mice were kept under pathogen-free conditions,
4 mice per cage with a 12 h light/dark cycle and an
ambient temperature of 22 ± 1 °C. Food and water were
available ad libitum.
All mice used for the mapping experiments were male
and were obtained from The Jackson Laboratory at 11–12
weeks of age, and were kept in our facility a minimum of
1 week prior to use in experiments. The specific strains
used to generate the mapping data included 129S1/SvImJ,
A/J, AKR/J, B10.D2-H2/n2SnJ, Balb/cJ, BTBR T+ Itpr3tf/J,
BUB/BnJ, C3H/HeJ, C57BL/6 J, CBA/J, DBA/2 J, FVB/NJ,
LG/J, LP/J, MA/MyJ, MRL/MpJ, NOD/LtJ, NZB/BlnJ,
NZO/HlLtJ, NZW/LacJ, SJL/J, SM/J and SWR/J as de-
scribed previously [18]. Mpdz transgenic mice on the
C57BL/6 background were obtained from our breeding
colony [27]. Littermate wild type and Mpdz +/− heterozy-
gous mice were also used at 11–12 weeks of age. All mice
used were male, and cohort sizes were 6–8 as noted in the
figure legends.
Chronic morphine administration
After baseline nociceptive testing, morphine sulphate
(Sigma) was administered to mice subcutaneously (s.c.)
20 mg/kg twice per day on days 1–3 and 40 mg/kg twice
per day on day 4 in 50–100 μl volumes of 0.9 % NaCl.
This protocol has been used to demonstrate opioid tol-
erance, dependence, hyperalgesia and other maladaptive
phenotypes in mice in previous experiments [13, 18].
Behavioral testing – mechanical thresholds
Mechanical withdrawal testing was performed as de-
scribed previously [14]. Briefly, mechanical nociceptive
thresholds were measured using von Frey fibers and the
“up-down” algorithm [49]. For these experiments mice
were acclimated on wire mesh platforms in plastic cylin-
ders. After acclimation, fibers of sequentially increasing
stiffness were applied to the plantar surface of a hind
paw according to the up-down paradigm. This testing
allowed the estimation of the mechanical withdrawal
threshold using curve fitting of the response data [50].
Final measurements were made approximately 18 h after
the administration of the final dose of morphine.
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Mechanical opioid-induced hyperalgesia (OIH) was cal-
culated as the percentage decrease in mechanical noci-
ceptive threshold resulting from repeated morphine
administration.
Morphine dose–response
Cumulative morphine dose–response curves were con-
structed as described previously [11, 12]. In order to
accomplish this, thermal tail flick latencies of gently re-
strained mice were measured with 0.1 s precision. Two
measurements were made per mouse. The lamp inten-
sity was the same for all strains. For the assessment of
morphine analgesic tolerance, these dose–response
experiments were made on morphine naïve mice and
again 18 h after the final dose of morphine was adminis-
tered. The cumulative doses of morphine used were
0,1,2,4,8,16 and 32 mg/kg s.c. Latency was determined
25 min after morphine administration as demonstrated
previously to be the time of peak morphine effect. The
parameter %MPE (percent maximal possible effect) was
determined according to the following formula:
%MPE ¼  measured latency‐baseline latencyð Þ=
cutoff latency‐baseline latencyð Þx100
Physical dependence
Physical dependence on morphine was measured using
previously reported methods [11, 12]. Mice were treated
with morphine for 4 days according to the standard mor-
phine administration protocol described above. To precipi-
tate withdrawal, naloxone (Sigma) 10 mg/kg was injected
s.c. in 50 μl 0.9 % NaCl. Mice were then placed in the same
clear cylinders used for the mechanical withdrawal thresh-
old assays. The number of jumps made during the 15 min
following naloxone injection was counted.
Weight measurement
Not reported previously for the dataset was the measure-
ment of weight. Animals were weighed individually imme-
diately prior to initiation of testing and morphine treatment
using a pan balance accurate to 0.01g. Animals were
again weighed after completion of the chronic morphine
administration paradigm. To calculate % weight change,
the following formula was used:
Final weight‐Initial weightð Þ=Initial weightð Þ x 100
Whole-genome haplotype-based computational genetic
mapping
Haplotype-based computational genetic mapping
(HBCGM) was conducted as described previously [18, 56],
and used to identify those genomic regions whose genetic
pattern was correlated with input phenotypic values for the
23 inbred strains utilized in these studies. In our previous
work we used tolerance, physical dependence, opioid-
induced hyperalgesia to mechanical and thermal hindpaw
responses and thermal tail flick data from these 23 strains
to discover an association of those traits with the Dcc gene
[18]. In the present work we used the same 5 datasets and
added weight change during morphine exposure. To facili-
tate computational mapping we converted the nociceptive
measurements to the fraction of baseline withdrawal
thresholds and latencies, and calculated the fold change in
morphine ED50 value as done in previous mapping studies
[9, 18, 57]. As described below, we also employed a false
discovery rate correcting procedure in the present work.
Filtering based on gene-wise false discovery rate (FDR) p value
Initial studies demonstrated that genes with a large size
and/or a high mutation rate (e.g. MHC region genes
such as Skint) were frequently identified as having a
strong association with an analyzed trait. Their large size
and/or high rate of polymorphism generated a large
number of different haplotypic patterns for these genes,
which increased the likelihood that genetic variation
within these genes would match a phenotypic response
pattern by chance. This problem was addressed using a
permutation test to compute a False Discovery Rate
(FDR) p value for each gene, which is the probability
that genetic variation within a gene matches a phenotype
by chance. To compute this p value, the mapping of
strain names to phenotype measurements was permuted
1,000 times, and HBCGM was then run on each of the
permuted phenotypes to produce 1,000 p values for each
gene. The FDR p value for each gene was then calculated
as the number of p values smaller than the original p
value, divided by the number of permutations (1,000).
For any genetic association where the FDR p value was
greater than 0.005, the gene was removed. This corre-
sponds to an association where the gene has matched
randomized data more than five times in the 1,000
permutations.
Integration of computational genetic mapping results across
related traits
HBCGM was first applied to evaluate each trait. For
some analyses, e.g. Table 2, the FDR correction was then
applied. To test the strength of association across all






In this calculation i = 1…n runs through all traits of
interest and p was defined as described above. In general,
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genes with multiple highly significant associations have
high scores and therefore are of higher interest.
Protein isolation and western blotting
After euthanization using CO2 asphyxiation, spinal cord
tissue was harvested by extrusion. Lumbar spinal cord tis-
sues were dissected on a chilled surface. Tissue was then
quick-frozen in liquid nitrogen and stored at −80 °C until
the time of analysis. Spinal cords were dissolved at 4 °C in
RIPA buffer (50 mM Tris–HCl, pH 8.0, 150 mM sodium
chloride, 1.0 % NP-40, 0.5 % sodium deoxycholate, and
0.1 % sodium dodecyl sulfate) to which a protease inhibi-
tor cocktail had been added (Roche). Aliquots of protein
were loaded on pre-cast SDS-PAGE (10 % Tris–HCl
acrylamide) gels, run and electrotransferred onto a polyvi-
nylidene difluorided membranes [54]. These blots were
probed with the primary MPDZ antibody (BD Transduc-
tion Laboratories, San Jose, CA) or CaMKII antibody
(Abcam) at 4 °C overnight. β-actin (Sigma) was used as an
internal control. The band intensity was quantified using
National Institutes of Health image J analysis software
(version 1.44).
Spinal cord synaptosome preparation
Spinal cord tissue was homogenized at 4 °C in the Syn-PER
Reagent (Thermo Scientific) in the presence of EDTA-free
the protease inhibitor cocktail (Roche). The homogenate
was centrifuged at 1200 × g for 10 min to remove cell deb-
ris, and the supernatant was then centrifuged at 15,000 × g
for 20 min. The pellets, containing synaptosomes, were
gently resuspended in the Syn-PER Reagent and maintained
on ice until use in co-immunoprecipitation experiments.
MUPP1 co-immunoprecipitation
Co-immunoprecipitation assays were performed using a
commercially available co-immunoprecipitation kit accord-
ing to the manufacturer’s protocol (Thermo Scientific).
Briefly, the protein concentration of each isolated synapto-
some sample was determined using the Pierce BCA Protein
Assay (Thermo Scientific). Equal amounts of synaptosome
samples (250 μg) were pre-cleared with control agarose
resin at 4 °C for 30 min. The supernatants were then
incubated with MUPP1 antibody (BD Transduction
Laboratories) or mouse IgG (Cell Signaling) overnight
at 4 °C to form immune complexes. To capture the im-
mune complexes, washed protein A/G agarose bead slurry
was added into the antibody/lysate samples and incubated
for 1 h at room temperature. After centrifugation at
3,000xg for 2 min, the beads were collected and washed
with ice-cold lysis buffer three times. Loading buffer was
added to the beads which were boiled for 5 min and then
centrifuged at 10,000× g for 5 min to dissociate proteins.
The co-immunoprecipitated proteins were subsequently
analyzed using Western blotting.
RNA isolation and analysis
Spinal cord samples from separate cohorts of mice were
dissected and stored as described above. For real-time
quantitative PCR, total RNA was isolated from spinal cord
tissue using the RNeasy Mini Kit (Qiagen) according to
the manufacturer’s instructions. The purity and concen-
tration were determined spectrophotometrically. Reverse
transcription was accomplished using a First Strand com-
plementary DNA Synthesis Kit (Invitrogen). Real-time
PCR was performed in an ABI prism 7900HT system (Ap-
plied Biosystems). All PCR experiments were performed
using the SYBR Green I master kit (Applied Biosystems).
All the primers were purchased from SABiosciences
(SABiosciences). Quantification was accomplished accord-
ing to the standard curve method. In order to achieve the
same PCR efficiency for each analyte, 1:10 serial dilutions
of cDNA were used to construct standard curves for
Mpdz and GAPDH. The R2 values for the standard curves
for each analyte approached 1.0, suggesting the same
amplification efficiency in the PCR reactions under these
conditions. Melting curves were performed to document
single product formation and agarose electrophoresis con-
firmed product size. As negative controls, RNA samples
that were not reverse transcribed were run. Data were
normalized to GAPDH mRNA expression.
Statistical analysis for behavioral data
All data are displayed as the means +/− SEM unless other-
wise noted. 1- or 2-Way ANOVA analysis was applied to
behavioral data with the Tukey test applied post-hoc
(Prism 5, GraphPad Software).
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